MedImmune LLC
http://www.medimmune.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MedImmune LLC
Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks
The South Korean biotech space has been marked by multiple positive R&D developments and pipeline and partnering progress in recent months, more than outweighing some other setbacks for the rapidly developing sector.
CARSgen Wins China’s Fifth CAR-T Approval But Pricing Dilemma Unresolved
As China’s fifth approved CAR-T cell therapy, CARSgen/Huadong’s zevorcabtagene autoleucel is priced at $159,735 for a single infusion. Expanding patient access will become a formidable task for the companies, due to the poor prospects of reimbursement coverage by China’s public medical insurance program.
GSK’s Blenrep Comeback On The Cards After Second Trial Win
The DREAMM-8 study was unblinded early thanks to strong interim results, giving Blenrep a shot at returning as a second-line or later treatment for multiple myeloma
Taking On Vyvgart In Myasthenia Gravis
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice